Administration of blocking (CTLA4, PD-1) or agonist (OX40) antibodies against these checkpoint regulators improves anti-tumor immune responses in animal models, and CTLA-4 and PD-1 antibodies have become approved immunotherapies for multiple tumor types in humans19–22,27–29. Here, TNFRSF4 is linked to neoplasm.